Gemdronic 5mg Injection is a prescription-strength intravenous formulation containing 5 mg of Zoledronic Acid in 100 mL solution. Zoledronic Acid is a highly potent bisphosphonate indicated primarily for oncology and bone health applications. This injectable medication is designed to inhibit osteoclast-mediated bone resorption, making it effective in reducing skeletal complications associated with malignancies such as bone metastases from solid tumors, multiple myeloma, and Paget's disease of bone. It is also used to treat hypercalcemia of malignancy by lowering elevated calcium levels that result from tumor-induced bone breakdown. Additionally, Gemdronic is indicated for osteoporosis treatment in postmenopausal women, males, and glucocorticoid-induced cases. Administered exclusively via intravenous infusion under healthcare provider supervision, Gemdronic offers long-lasting bone protection with infrequent dosing schedules, particularly beneficial in oncology settings. The product comes in a single-dose 100 mL vial containing 5 mg Zoledronic Acid and requires proper storage below 30°C away from light. It is essential to maintain adequate patient hydration during therapy to minimize kidney risks, as the drug is contraindicated in patients with severe renal impairment. Gemdronic 5mg Injection is a critical therapeutic agent supplied for hospital and oncology use to manage bone-related complications in cancer patients effectively.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Zoledronic Acid 5 mg per 100 mL |
| Formulation | Sterile injectable solution for intravenous infusion |
| Therapeutic Uses | Treatment of hypercalcemia of malignancy, bone metastases, multiple myeloma, osteoporosis, and Paget's disease of bone |
| Mechanism of Action | Inhibits osteoclast activity to reduce bone resorption and calcium release |
| Dosage Regimen | 5 mg once yearly for osteoporosis; 4 mg every 3-4 weeks for oncology indications |
| Administration Route | Intravenous infusion only |
| Packaging | Single-dose vial containing 100 mL solution |
| Storage Requirements | Store below 30°C, do not freeze, protect from light |
| Use Restrictions | For hospital/oncology use only; not for use in severe renal impairment |
| Additional Requirements | Adequate hydration and possible calcium/vitamin D supplementation required |
| Attributes | Description |
|---|---|
| Generic Name | Zoledronic Acid |
| Brand Name | Gemdronic |
| Concentration | 5 mg/100 mL |
| Therapeutic Category | Oncology / Bone Health (Bisphosphonate) |
| Indications | Hypercalcemia of malignancy, Bone metastases, Multiple myeloma, Osteoporosis, Paget's disease of bone |
| Dosage Forms | Injectable solution |
| Route of Administration | Intravenous infusion |
| Manufacturer | Multiple brands including Gemdronic |
| Storage Conditions | Store below 30°C, avoid freezing, protect from light |
| Packaging | Single-dose vial of 100 mL |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
For oncology indications such as bone metastases, the recommended dosage of Gemdronic is 4 mg administered via intravenous infusion every 3 to 4 weeks. The dosage frequency can vary depending on the patient's renal function and specific cancer treatment plan.
Yes, Gemdronic 5mg Injection is approved for osteoporosis treatment with a recommended dose of 5 mg administered once yearly as an intravenous infusion.
Gemdronic Injection must be stored below 30°C, should not be frozen, and must be protected from light to maintain stability and effectiveness.
Gemdronic is not recommended for use in patients with severe kidney impairment due to risk of nephrotoxicity. Renal function should be assessed before administration, and adequate hydration is essential.
Gemdronic should be administered intravenously under strict medical supervision with patient hydration before and after infusion to reduce kidney toxicity. Calcium and vitamin D supplementation may also be necessary during treatment.
Country Of Origin: India
Product Name: Gemdronic 5mg Injection
Generic Name: Zoledronic Acid 5 mg/100 mL
Manufacturer:
(Marketed under various oncology/critical care brands; “Gemdronic” is one such brand)
Therapeutic Category:
Oncology / Bone Health (Bisphosphonate)
Product Description:
Gemdronic Injection contains Zoledronic Acid, a potent bisphosphonate that inhibits bone resorption.
It is commonly used to treat hypercalcemia of malignancy, bone metastases, multiple myeloma, and osteoporosis.
By blocking osteoclast-mediated bone breakdown, Zoledronic Acid strengthens bone, reduces skeletal complications, and helps lower elevated blood calcium levels caused by cancers.
Indications:
• Hypercalcemia of malignancy (tumor-induced high calcium levels)
• Bone metastases from solid tumors
• Multiple myeloma (skeletal-related events prevention)
• Osteoporosis (postmenopausal, glucocorticoid-induced, male osteoporosis)
• Paget’s disease of bone
Mechanism of Action:
• Zoledronic Acid binds to bone mineral and inhibits osteoclast activity, reducing bone resorption.
• Decreases release of calcium from bone, preventing skeletal complications.
Dosage & Administration:
• Administered as intravenous infusion only.
• 5 mg once yearly (for osteoporosis).
• 4 mg every 3–4 weeks (for oncology indications such as bone metastases).
• Dose and frequency depend on indication and patient’s renal function.
(Must be given by a healthcare professional under strict supervision.)
Key Benefits:
• Reduces risk of fractures and bone complications in cancer patients.
• Long-lasting bone protection with infrequent dosing.
• Effective in lowering high calcium levels caused by tumors.
Packaging:
• Single-dose vial: 100 mL solution containing 5 mg Zoledronic Acid.
Storage:
• Store below 30°C.
• Do not freeze.
• Protect from light.
Important Notes:
• For hospital/oncology use only.
• Not recommended in patients with severe kidney impairment.
• Adequate hydration before and after infusion is essential.
• Calcium and vitamin D supplementation may be required during treatment.
ONCOLOGY SUPPLIER
Melizza Lifescience
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
